Pliant Therapeutics, Inc. (PLRX)
PLRX Stock Price Chart
Explore Pliant Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PLRX price movements and trends.
PLRX Company Profile
Discover essential business fundamentals and corporate details for Pliant Therapeutics, Inc. (PLRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Jun 2020
Employees
171.00
Website
https://pliantrx.comCEO
Bernard Coulie
Description
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
PLRX Financial Timeline
Browse a chronological timeline of Pliant Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.33.
Earnings released on 11 May 2026
EPS came in at -$0.32 surpassing the estimated -$0.36 by +11.11%.
Earnings released on 11 Mar 2026
EPS came in at -$0.35 surpassing the estimated -$0.42 by +16.67%.
Earnings released on 6 Nov 2025
EPS came in at -$0.43 surpassing the estimated -$0.53 by +18.87%.
Earnings released on 7 Aug 2025
EPS came in at -$0.71 falling short of the estimated -$0.62 by -14.52%.
Earnings released on 8 May 2025
EPS came in at -$0.92 falling short of the estimated -$0.78 by -17.95%.
Earnings released on 3 Mar 2025
EPS came in at -$0.82 surpassing the estimated -$0.99 by +17.17%.
Earnings released on 7 Nov 2024
EPS came in at -$0.95 surpassing the estimated -$0.99 by +4.04%.
Earnings released on 7 Aug 2024
EPS came in at -$0.92 falling short of the estimated -$0.85 by -8.24%.
Earnings released on 6 May 2024
EPS came in at -$0.78 falling short of the estimated -$0.76 by -2.63%.
Earnings released on 27 Feb 2024
EPS came in at -$0.69 surpassing the estimated -$0.81 by +14.81%, while revenue for the quarter reached $4.84m , beating expectations by +494.51%.
Earnings released on 9 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$0.78 by +10.26%.
Earnings released on 9 Aug 2023
EPS came in at -$0.70 surpassing the estimated -$0.73 by +4.11%, while revenue for the quarter reached $248.00k , missing expectations by -71.82%.
Earnings released on 9 May 2023
EPS came in at -$0.67 falling short of the estimated -$0.66 by -1.52%, while revenue for the quarter reached $1.33m , beating expectations by +10.08%.
Earnings released on 9 Mar 2023
EPS came in at -$0.72 falling short of the estimated -$0.70 by -2.86%, while revenue for the quarter reached $1.97m , beating expectations by +35.46%.
Earnings released on 8 Nov 2022
EPS came in at -$0.65 surpassing the estimated -$0.74 by +12.16%, while revenue for the quarter reached $1.48m , missing expectations by -17.32%.
Earnings released on 8 Aug 2022
EPS came in at -$0.82 matching the estimated -$0.82, while revenue for the quarter reached $4.99m , beating expectations by +269.59%.
Earnings released on 9 May 2022
EPS came in at -$0.78 falling short of the estimated -$0.77 by -1.30%, while revenue for the quarter reached $1.25m , missing expectations by -0.87%.
Earnings released on 28 Feb 2022
EPS came in at -$0.68 surpassing the estimated -$0.76 by +10.53%, while revenue for the quarter reached $2.00m , missing expectations by -33.37%.
Earnings released on 9 Nov 2021
EPS came in at -$0.75 falling short of the estimated -$0.71 by -5.63%, while revenue for the quarter reached $1.61m , missing expectations by -8.00%.
Earnings released on 9 Aug 2021
EPS came in at -$0.64 matching the estimated -$0.64, while revenue for the quarter reached $1.79m , meeting expectations.
PLRX Stock Performance
Access detailed PLRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
